Targeted, LCMS-based Metabolomics for Quantitative Measurement of NAD\(^+\) Metabolites

Samuel AJ Trammell \(^ab\), Charles Brenner \(^ab\)*

Abstract: Nicotinamide adenine dinucleotide (NAD\(^+\)) is a coenzyme for hydride transfer reactions and a substrate for sirtuins and other NAD\(^+\)-consuming enzymes. The abundance of NAD\(^+\), NAD\(^+\) biosynthetic intermediates, and related nucleotides reflects the metabolic state of cells and tissues. High performance liquid chromatography (HPLC) followed by ultraviolet-visible (UV-Vis) spectroscopic analysis of NAD\(^+\) metabolites does not offer the specificity and sensitivity necessary for robust quantification of complex samples. Thus, we developed a targeted, quantitative assay of the NAD\(^+\) metabolome with the use of HPLC coupled to mass spectrometry. Here we discuss NAD\(^+\) metabolism as well as the technical challenges required for reliable quantification of the NAD\(^+\) metabolites. The new method incorporates new separations and improves upon a previously published method that suffered from the problem of ionization suppression for particular compounds.

Introduction

The essentiality of NAD\(^+\)-dependent processes in fuel utilization, gene regulation, DNA repair, protein modification, and cell signaling events makes the analysis of NAD\(^+\) metabolites central to an understanding of what a tissue is doing. NAD\(^+\) is the key hydride transfer coenzyme for a wide variety of oxidoreductases and is also the consumed substrate of sirtuins, poly adenosine diphosphate ribose (ADPr) polymerase, mono ADPr transferases, and cyclic ADPr synthases [1,2]. Measurement of NAD\(^+\) and related metabolites including several nucleosides and nucleotides (hereafter, the NAD\(^+\) metabolome) serves as a powerful indicator of the ability of a cell or tissue to perform processes such as glycolysis, gluconeogenesis, fatty acid oxidation, reactive oxygen species detoxification, among others. Moreover, the state of the NAD\(^+\) metabolome can serve as an indication of nutrition, health and disease.

Because NAD\(^+\) and related metabolites vary in cellular concentration from ~1 \(\mu\)M to ~1 mM, the analytical procedure must be robust, reproducible, and rapid. Liquid chromatography (LC)-based assays afford the ability to measure multiple metabolites in a timely fashion with the duration of each run ranging from 10 minutes to an hour. However, quantification through HPLC-UV-vis methods is severely compromised based on the complexity of samples. In complex mixtures, a single peak may contain the metabolite of interest in addition to many other metabolites of identical retention time. In addition, peak shapes are rarely unaffected by complexity. Some investigators use a UV-vis signal at a retention time as the metabolite. This process leaves a great deal of data in the dark. Because every NAD\(^+\) metabolite can be converted to one or more other metabolites, snapshots of the levels of NAD\(^+\), nicotinamide (Nam) or any other NAD\(^+\) metabolite without assessment of the NAD\(^+\) metabolome on a common scale has the potential to be misleading.

Because of its specificity and sensitivity, LC coupled to mass spectrometry (LC-MS) is a leading analytical method in the measurement of small molecules in complex samples. As with HPLC-UV-vis methods, LC serves to separate compounds of interest and must be optimized in the same way as any HPLC method. Because all LC-MS data contain at least two dimensions of data (retention time plus the masscharge ratio, termed \(m/z\)), LC-MS increases specificity with respect to LC-UV-vis methods that report complex absorbance spectra as a function of retention time or matrix-assisted laser desorption ionization (MALDI)-based methods that report complex \(m/z\) data without retention times. Multidimensional MS, i.e., LC-MS\(^2\), provides further information because a particular analyte breaks down to component ions at a particular ionization energy. An ideal LC-MS method identifies an optimal extraction and separation method for all molecules of interest, detects the compounds in either negative or positive ion mode MS, and has sufficient LC separation to subject each molecule of interest to MS\(^2\) analysis. The method is then a series of selective reaction monitoring (SRM) protocols in which analytes are identified and quantified by MS as they come off the LC.

Whereas metabolomic discovery projects require high mass resolution instruments, targeted quantitative LC-MS assays can make use of lower resolution tandem mass spectrometers such as triple quadrupoles (QQQ). Here, the multidimensional data (retention time, \(m/z\), and MS\(^2\) transitions) are used to distinguish closely related metabolites, such as NAD\(^+\) from NADH. Limits of quantification in optimized targeted, quantitative LC-MS assays are in the femtomole range.

Though mass spectrometers offer great analytical power for measuring the NAD\(^+\) metabolome, they also present technical challenges not encountered in other analytical techniques. These challenges include development of optimal mass spectrometry conditions, proper separation of metabolites, and the best choice of internal standards. Here we discuss NAD\(^+\) metabolism and describe an optimized LC-MS\(^2\) assay of the NAD\(^+\) metabolome.

*Department of Biochemistry
*Interdisciplinary Graduate Program in Genetics
Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA

*Corresponding author. Tel.: +1 3193357934; Fax: +1 3193359570
E-mail address: charles-brenner@uiowa.edu (Charles Brenner)
**NAD⁺ Transactions**

In fungi and vertebrates, NAD⁺ concentration is maintained by either *de novo* synthesis from tryptophan [4] or through salvage of nicotinic acid (NA) [5], nicotinamide (Nam) [6], and the recently identified NAD⁺ precursor vitamin, nicotinamide riboside (NR) [7]. Some organisms, such as *Candida glabrata*, lack *de novo* synthesis [8]. Many vertebrate cell types turn this pathway off [2]. *De novo* synthesis proceeds from tryptophan in six steps to produce nicotinic acid mononucleotide (NAMN) and in two additional steps to produce NAD⁺. When NAD⁺ is the substrate of an enzyme such as glyceraldehyde phosphate dehydrogenase (GAPDH), fuel oxidation reactions will reduce NAD⁺ to NADH. In the case of GAPDH, the reaction is reversible, such that NADH is reoxidized to NAD⁺ in the gluconeogenic direction. NAD⁺ and NADH can be phosphorylated to NADP⁺ and NADPH. NADP⁺ is required for the pentose phosphate pathway (PPP), which produces NADPH. NADPH is required for detoxification of reactive oxygen species and reductive biosynthesis of lipids and steroids. Just as glucose-6-phosphate oxidation by the PPP produces NADPH, glutathione reactivation and reductive biosynthesis reoxidizes NADPH to NADP⁺.

Beyond serving as a coenzyme in hydride reactions, NAD⁺ is a consumed substrate for enzymes such as sirtuins, PARPs, and other ADPr transfer enzymes [1,2,9,10]. Though CD38 has an activity on NADP⁺, at least in vitro [11], the typical activity of an NAD⁺-consuming enzyme involves NAD⁺ as the substrate, and products that include Nam and an NAD⁺-derived ADPr moiety. Thus, to sustain intracellular NAD⁺ levels, actions of NAD⁺-consuming enzymes must be accompanied by Nam salvage [1,2]. Nam salvage differs between fungi and vertebrates. In fungi, Nam is hydrolyzed by the *Pnc1* encoded nicotinamide dehydrogenase [6]. NA is then converted by the first enzyme of the Preiss-Handler pathway, the *Npt1* encoded NA phosphoribosyltransferase, to form NAMN. The second and third steps of Preiss-Handler salvage correspond to the final two steps of *de novo* synthesis, whose last step is glutamine-dependent NAD⁺ synthetase [12]. In vertebrates, Nam produced as a product of NAD⁺-consuming enzymes cannot be salvaged as NA intracellularly. However, if Nam goes through the gut, bacterial nicotinamidases produce NA [13], which circulates and is used via Preiss-Handler salvage.

Intracellular Nam salvage in vertebrates depends on a Nam phosphoribosyltransferase, which entered the scientific literature with the names pre-B cell colony enhancing factor (PBEF) [14] and Visfatin [15]. Now termed Nampt, this protein is widely expressed along with CD73, a homolog of NMPK, which circulates and is used via Preiss-Handler salvage.

Figure 1. NAD⁺ Biosynthesis in yeast and vertebrates. Intracellular NAD⁺ is derived from either *de novo* synthesis from tryptophan or from salvage of NA, Nam, or NR. In yeast, Nam is converted to NA by nicotinamide dehydrogenase (Nampt) (dotted line). In yeast and vertebrates, NA is phosphorylated to NAMN, an intermediate in *de novo* synthesis, and converted to NAD⁺ by way of NAA in a step catalyzed by glutamine-dependent NAD⁺ synthetase [12]. In vertebrates, Nam conversion to NMN is catalyzed by Nampt [16]. The other source of NMN in yeast and vertebrates is phosphorylation of NR by NR kinases. NR and NAD can be split to the corresponding pyridine bases. NAR phosphorylation yields NAMN. NMN is converted to NAD⁺ via NAAD in a step catalyzed by glutamine-dependent NAD⁺ synthetase [12]. In vertebrates, Nam produced as a product of NAD⁺-consuming enzymes cannot be salvaged as NA intracellularly. However, if Nam goes through the gut, bacterial nicotinamidases produce NA [13], which circulates and is used via Preiss-Handler salvage.

Intracellular Nam salvage in vertebrates depends on a Nam phosphoribosyltransferase, which entered the scientific literature with the names pre-B cell colony enhancing factor (PBEF) [14] and Visfatin [15]. Now termed Nampt, this protein is widely expressed along with CD73, a homolog of NMPK, which circulates and is used via Preiss-Handler salvage.
from S-adenosyl-methionine [19,20]. The corresponding Nam N-methyltransferase (NNMT) has been well characterized in vertebrates [21]. Increased NNMT expression has been observed in Parkinson’s Disease [22] with a potential role in disease etiology [23,24]. NNMT is also increased in malignancy [25] and plays an apparent role in cell migration [26]. Despite the reported roles in disease, N-methyl Nam (NMN) is a natural metabolite in healthy individuals with reported antithrombotic [27] and vasorelaxant [28] activities that is increased in plasma and urine after endurance exercise [29]. NMN is ultimately converted to N1-Methyl-2-pyr dine-5-carboxamide and N1-Methyl-4-pyridine-5-carboxamide.

Though the primary breakdown product of NAD+ is Nam and the complete bacterially digested product is NA, nicotinamide riboside (NR) is an additional salvageable precursor that exists intracellularly and in milk [3,7,30]. The unique NR salvage pathway is via nicotinamide riboside kinases [7]. In addition, NR can be split into a Nam moiety and resynthesized to NAD+ via Nam salvage enzymes [31]. Nicotinic acid riboside (NAR) is an alternate substrate of nicotinamide riboside kinases [32] and purine nucleoside phosphorylase [13] that has been shown to be an intracellular NAD+ precursor [30] but has not been reported to circulate.

Whereas NA is the salvageable precursor of NAD+ that has been exposed to the most digestive enzymes and Nam is the salvageable precursor that is produced by every cell with NAD+-consuming enzymes, the main source of dietary NR is probably partial digestion of NAD+. Depending on one’s nutrition and potentially one’s microbiome, the three vitamin precursors of NAD+ (NA, Nam and NR) and trp should be in circulation [2]. The existence of extracellular enzymes with the potential to produce and consume NMN, and which consume NAD+, suggests the circulation of pyridine nucleotides [1]. Moreover, NMN supplementation of mice on high fat diet (HFD) increases insulin sensitivity, glucose tolerance, and intracellular NAD+ compared to non-treated mice on the same diet [33]. Though extracellular NMN was interpreted to function via direct incorporation of the nucleotide into cells [33], careful examination indicates that extracellular NA, Nam, and NR increase intracellular NAD+ in yeast and vertebrate cells, whereas NMN requires dephosphorylation to NR [34]. Consistent with the prediction that the ectoenzyme CD73 has NMN 5’-nucleotidase activity [1], CD73 has the requisite biochemical activity to catalyze NMN dephosphorylation [35]. In the yeast system, NR extends replicative longevity in a manner that depends on conversion to NAD+ [31]. In mice on high fat diet, NR improves glucose control and insulin sensitivity, while moderating the observed increase in adiposity [36].

In addition to the major difference in Nam salvage between vertebrate and yeast systems, there is a mitochondrial compartmentalization problem in vertebrates. In yeast, transporters Nad1 and Nad2 carry NAD+ across the mitochondrial inner membrane [37] and the only mitochondrial NAD+ biosynthetic enzyme is NADH kinase, Pos5 [38]. However, in vertebrate cells, the nucleocytosplasm and the mitochondrial matrix constitute distinct pools of NAD+, NADH, NADP+ and NADPH owing to impermeability of the mitochondrial inner membrane to these compounds. Though systems such as the malate-aspartate shuttle and nicotinamide nucleotide transhydrogenase transfer reducing equivalents across mitochondrial membranes, vertebrate mitochondria require a system to import an NAD+ precursor into the matrix for conversion to NAD+. On the basis of localization of NAD+ biosynthetic enzymes, that precursor is NMN [34]. Nmnat3, which converts NMN to NAD+, is localized to the mitochondrial matrix. Nmnat3 is one of three vertebrate NAMN/NMN adenyltransferases—the other two are localized in the nucleus and on the cytosolic face of Golgi. Though one could argue that the ability of Nmnat3 to convert NAMN to NAAD suggests that NAMN or NMN could be the mitochondrial NAD+ precursor, the NAAD product of the NAMN reaction requires glutamine-dependent NAD+ synthetase for conversion to NAD+. Glutamine-dependent NAD+ synthetase is not mitochondrially localized [34].

As shown in Figure 1, the implication of NMN as the limiting precursor for vertebrate mitochondrial NAD+ biosynthesis is profound. De novo synthesis and NA-dependent Press-Handler synthesis can only supply mitochondria with NAD+ by nucleocytosolic conversion to NAD+ followed by the pyrophosphate-dependent conversion of NAD+ to NMN in a back reaction of Nmnat first demonstrated by Arthur Kornberg in 1948 [39] or by conversion of NAD+ to Nam and subsequent conversion of Nam to NMN. In contrast, Nam and NR can be converted directly to NMN by Nampt and NR kinases, respectively.

In mitochondria that are burning fuel, the redox reactions are largely directional because fuel oxidation converts NAD+ to NADH and complex I of the electron transfer chain reoxidizes NADH to NAD+. Three vertebrate sirtuins, Sirt3-5, reside in mitochondria, where they consume NAD+ in reactions that either modify proteins or relieve protein modifications [40]. For the mitochondrial sirtuins to work and avoid robbing redox enzymes of NAD+, NMN must be imported from the cytosol.

Completing the major NAD+ transactions, yeast possess two cytosolic NAD+/NADH kinases and the mitochondrial NADH kinase, Pos5 [38]. Vertebrate cytosolic NAD+/NADH kinase is related to the yeast enzymes [41], whereas the vertebrate mitochondrial NAD+/NADH kinase was recently identified as a homolog of A. thaliana Nadk3, which can use ATP or polyphosphate as the phosphate donor [42].

### Quantitative NAD+ Metabolomics

The NAD+ metabolome, as defined here, includes dinucleotides, nucleotides, nucleosides, nucleobases and related compounds (Table 1). The masses of many of the analytes differ by a single Dalton, necessitating optimal separation and careful MS. The current method is an improvement over methods, which measured only select metabolites [17,43], and more recent methods, which embraced a more complete set of metabolites, but which lacked resolution of several compounds [3,44]. Here we review optimization of all parameters and a solution to the ionization suppression problem that plagued previous methods.

### Optimized extraction

Methods that do not inactivate enzymatic activities upon cell lysis [44] are clearly flawed and, based upon the amount of time of sample autolysis, cellular NAD+ can be degraded to ~1% of expected values (~10 μM) with elevation of apparent NR concentration to ~100 times expected values (1 mM) [45]. The preferred method of extraction is to use boiled, buffered ethanol [46], which is well validated for NAD+ metabolites [3,30].

For yeast samples, an ideal cell number is 2 to 4.5 x 107, the midrange of which can be obtained by harvesting 25 ml of cells at an OD600 nm of 0.7. For mammalian cell culture, we typically use 4 to 20 x 106 cells, depending upon the cell type. Yeast cell pellets are extracted directly. Mammalian cell pellets are washed once in ice-cold potassium buffered saline. Cells are resuspended in 300 μL of a 75% ethanol/25% 10 mM HEPES, pH 7.1 (buffered ethanol) solution, preheated to 80 °C. Samples are shaken at 1000 rpm in an 80 °C block for three minutes. Soluble metabolites are separated.
from particulate by refrigerated microcentrifugation (10 min, 16kg). Though the ethanol-soluble extract contains all the metabolites of interest, the weight of the particulate can be used to determine the optimized resuspension volume for dried metabolites. Thus, both the particulate and soluble metabolites are dried by speed vacuum at 40 °C.

Empirically, we determined that 3.6 mg of yeast or mammalian cell-derived particulate corresponds to a metabolite pellet, which can be resuspended in a 100 µl volume and produce the desired absorbance and LC-MS signals. Thus, the dry weight of each pellet is recorded, divided by 3.6 mg, and multiplied by 100 µl to obtain the initial resuspension volume. Extracts are resuspended in 1% (v/v) acetic acid adjusted to pH 9 with ammonium hydroxide (ammonium acetate buffer). These conditions were chosen to preserve NADH and NADPH prior to analysis [47].

Resuspended metabolites (2 µl) are checked in a Nanodrop (ThermoFisher) to determine the OD_{260 nm}, which is typically greater than or equal to 14. The remaining volume is diluted to an OD_{260 nm} of 14 in ammonium acetate buffer to obtain the final resuspension volume. For LC-MS, this material is diluted two-fold into two different metabolite standards and 2.5 µl of the resulting material is injected and analyzed. Because these dilutions convert the total intracellular volume into a known volume of which an effective volume of 1.25 µl is analyzed, it is straightforward to calculate the intracellular volume of cells under analysis.

The calculation of intracellular volume is as follows. For yeast cells, the intracellular volume of a single cell is taken as 70 fl [48]. Thus, the calculated intracellular volume is obtained as 70 fl times the cell number. For mammalian cells, we use 2.5 pl as volume of a HeLa cell [49] and calculate the total extracted intracellular volume in the same way as for yeast cells. For example, an extraction of 3 x 10^7 yeast cells has a calculated intracellular volume of 2.1 µl. If this sample were resuspended into 100 µl and require no further adjustment after checking on the Nanodrop, the 1.25 µl of cell extract in a 2.5 µl injection would represent 1.25% of 2.1 µl = 26 nl. Because the internal standards permit metabolites to be quantified on a mol scale, intracellular metabolite concentrations are determined, in this example, as mol of metabolite divided by 2.6 x 10^4 l.

Optimized internal standards

Ionization suppression is the tendency for sample components to dampen the ionization and detectability of particular analytes. Thus, one cannot reliably depend on the peak height or area of a metabolite in a standard curve of purified metabolites to be on the same scale as its peak size in a complex mixture. In the most advanced previous quantification method for NAD^+ metabolites, ionization suppression was a problem for NAD^+, inosine and NA [3].

Two internal standard sets are employed. One set is used to quantify 16 metabolites (all analytes except NR, Nam, and NA) and is used in an alkaline separation. The other set is used to quantify NR, Nam, and NA in an acidic separation.

For analytes in the alkaline separation, an extract of Fleischmann’s yeast metabolites is prepared from cells grown in 99% uniformly labeled 18O glucose (Icon Isotopes, Summit, New Jersey). In the course of this culture, the PPP converts 13C glucose to 13C ribose-5-phosphate, such that all of the cells’ nucleic acids, mononucleotides and dinucleotides incorporate 13C. Mononucleotides incorporate 5 additional Da from one ribosyl moiety, whereas dinucleotides incorporate 10 additional Da from two ribosyl moieties. Complete incorporation is achieved by growing two serial starter cultures in 13C glucose synthetic dextrose complete media, followed by inoculation of a 250 ml volume of 13C glucose media at a starting OD_{590} of 0.2 and growth to OD_{590} of 0.8. Cells in 50 ml aliquots are then pelleted and stored at -80 °C prior to extraction with 300 µl buffered ethanol solution. Metabolites are resuspended in 100 µl of the ammonium acetate buffer and have a typical OD_{260 nm} of 100. For LC-MS, Fleischmann’s extract is diluted 1:40 into ammonium acetate buffer. This diluted Fleischmann’s extract is further diluted 1:1 with experimental samples. In the LC-MS analysis, 2.5 µl of the fully diluted material is injected. This material represents 1.25 µl of the experimental extract and an appropriate amount of Fleischmann’s extract for metabolite quantification.

Because the vitamins Nam and NA do not contain a carbohydrate group, they are not labeled by heavy labeled glucose and require the second set of internal standards for accurate quantification. To each sample or standard solution, heavy labeled Nam and NR are added such that the final concentration is 1.5 µM. 18O labeled Nam is prepared by tetramethylguanidine- catalyzed hydrolysis with 3-cyano- pyridine and H_218O, as described [50]. Though heavy NR is present in the Fleischmann’s yeast extract standard, NR is best separated and quantified in an acidic separation with Nam and NA. Heavy labeled NR is made as described [51].

We prepare stock solutions (typically at 10 mM) of each metabolite to be quantified and then prepare a set of standard solutions containing the whole set of metabolites to be quantified at a range of concentrations (0, 0.1, 0.2, 0.6, 2, 6, 20, 60, and 200 µM). For the alkaline separation, these standards are mixed 1:1 with the 1:40 dilution of Fleischmann’s extract so that each quantifiable metabolite in the extract can be set to a pmol amount. For example, if a particular metabolite in the Fleischmann’s sample were to interpolate precisely between the 2 µM and 6 µM standards (1 µM and 3 µM) in the 2.5 µl injected volume, we would calculate there to be 5 pmol of that metabolite in the standard amount of Fleischmann’s extract that will be used for all subsequent samples. This determination is made in technical replicates. Importantly, we cannot expect the 5 pmol peak area of that metabolite to remain constant when Fleischmann’s extract is mixed with experimental yeast extracts because peak shapes are often distorted, and ionization is suppressed due to sample complexity. However, because the 13C metabolites in Fleischmann’s extract will have the same degree of ionization suppression as the 12C metabolites in the experimental extract, the peak area ratios of 12C to 13C metabolites and the known mol amounts of the Fleischmann’s metabolites allow calculation of the amounts of the experimental metabolites. Molar calculation of the Fleischmann’s metabolites are not performed. Mol amounts of metabolites in the experimental samples are converted to molar using the calculation of intracellular volume described above. Because the IMP peak in Fleischmann’s extract is quite small, we use relative peak areas of IMP and NMN in the standard solutions to derive a correction factor that allows IMP in experimental samples to be quantified against the Fleischmann’s NMN peak. For each metabolite, the peak area used for quantification is that of the MS1 transition.

In theory, inclusion of 1.5 µM 18O labeled Nam and 18O labeled NR should be sufficient to quantify nonlabeled Nam and NR in the experimental extracts. In practice, because label incorporation may vary and there is greater accuracy in preparation of 10 mM standards than 1.5 µM radiolabeled standards, we quantified the 18O peaks of Nam and NR against a standard curve of NA, Nam and NR. These analyses result in a mol amount of heavy Nam and NR determined from the light standards. Because the same amount of heavy Nam and NR will be in all experimental samples, relative peak areas allow conversion of experimental Nam and NR peaks to mol and molar. The peak area ratio between heavy Nam and NA in the standard solutions is used to derive a correction factor that allows the heavy Nam peak to calculate the amount of NA in experimental samples.
Figure 2. Chromatograms of all 19 metabolites generated from injection of complex standard solutions using MRM LC-MS. All compounds were detected in positive ion mode in alkaline (A) and acidic (B) separations. Multiple peaks observed in Uridine and NA illustrate cross talk from other metabolites in mixture. In the case of Uridine, the early eluting peak is the result of the $^{13}$C peak of Cytidine. NA later eluting peaks are the result of $^{13}$C peaks from Nam produced either from the Nam standard or on-source fragmentation of NR to Nam.
**Optimized liquid chromatography**

Earlier, we described an assay of the NAD⁺ metabolome based on hydrophilic interaction liquid chromatography [3]. Encouraged by its track record for separation of nucleosides and nucleotides [52-54], we have since developed an improved separation with the porous graphitic carbon reversed phase material, Hypercarb (Thermo). Resolution of all compounds is done with two different mobile phases on two Hypercarb columns, each used solely for one separation.

### Table 1. Alkaline separation gradient.

| Time (min) | Solvent B (%) | Column Volumes |
|------------|---------------|----------------|
| 0          | 5             | -              |
| 1.8        | 5             | 1.8            |
| 14         | 54            | 12.4           |
| 14.1       | 90            | -              |
| 17.1       | 90            | 3              |
| 17.2       | 5             | -              |
| 32.2       | 5             | 15.3           |

In the alkaline separation, solvent A is 7.5 mM ammonium acetate with 0.05% (v/v) ammonium hydroxide and solvent B is 0.05% (v/v) ammonium hydroxide in acetonitrile. The optimized gradient is described in Table 1 with a flow rate of 0.08 ml/min and a column temperature of 60 °C. As shown in Table 1, the complete run takes 32.2 min on a 1 mm x 100 mm Hypercarb column and must be equilibrated for 20 min prior to first injection.

In the acid separation, solvent A is 10 mM ammonium acetate with 0.1% formic acid and solvent B is 0.1% formic acid in acetonitrile. The optimized gradient is described in Table 2 with a flow rate of 0.2 mL/min and a column temperature of 60 °C. As shown in Table 2, the complete run takes 23.4 min on a 2.1 mm x 100 mm Hypercarb column. Extracted ion currents for each resolved metabolite are provided in Figure 2.

### Table 2. Acidic separation gradient.

| Time (min) | Solvent B (%) | Column Volumes |
|------------|---------------|----------------|
| 0          | 5             | -              |
| 1.8        | 5             | 1              |
| 11.2       | 35.9          | 5.4            |
| 11.3       | 90            | -              |
| 13.3       | 90            | 1.2            |
| 13.4       | 5             | -              |
| 23.4       | 5             | 5.8            |

**Mass Spectrometry Optimization**

The power of triple quadrupole mass spectrometers is the ability to perform multiple SRM protocols in a single run, i.e. multiple reaction monitoring (MRM). Modern QQQs, such as the Waters Acquity TQD employed herein, are equipped with automatic optimization software to detect transitions and optimize ionization. The software can be the best friend and greatest enemy in method development. Since many of the metabolites are of similar structure and mass, specific diagnostic fragments must be identified and optimized. The carboxylic acid versus carboxamide metabolites and the oxidized versus reduced metabolites differ by only one Dalton. The ¹³C peaks produced from metabolites such as NAD⁺ and NADPH would produce crosstalk with NADH and NADPH, respectively (Figure 2A). However, all four compounds produce diagnostic fragments, allowing for specific quantification. Current automatic optimization software identifies fragments that are mostly easily produced and not necessarily those that are diagnostic for the metabolite in the context of structural similarities in the NAD⁺ metabolome. Online searchable libraries such as Metlin (http://metlin.scripps.edu/) and Massbank (http://www.massbank.jp/?lang=en) provide MS/MS spectra for many metabolites with identified fragment structures [55,56]. Specific fragments for NADH and NADPH not identified by the automatic software were chosen based on these searches. The transitions were optimized manually. Transitions and optimized conditions are detailed in Table 1.

The cone voltage must be optimized when measuring NAD⁺ especially for NR, NAR, NAMN, and NMN to reduce on-source fragmentation. NR and NMN readily produce Nam signal, whereas NAR and NAMN produce NA signal (Figure 2B, Nam extracted ion current). Optimization of cone voltage decreases but does not completely remove crosstalk. This unavoidable crosstalk greatly illustrates the need for robust LC separation.

After development, overall robustness was determined based on the capacity factors (k’), quantitative range, linear goodness of fit (R²), replicative standard deviation (RSD) of the method, and RSD of the system. Capacity factors were above 2 for all analytes with the exception of CMP (k’ = 1) (Table 1). Standard curves were linear from 0.125 picomoles to 250 picomoles with R² values falling above 0.99 for all but NAR (0.948), inosine (0.974), NR (0.981) and NADH (0.988). RSD of the method was measured with six separate standard solutions at 10 µM concentrations. RSD of the system was measured with four injections of the same standard solution. Method RSDs were below 10% for all but cytidine, NAR, inosine, NAMN, ATP, NAAD, NADH, and NADP. System RSDs were below 10% for all but cytidine and NAR. Limits of quantification (LOQ) were measured empirically and defined as the concentration producing a signal-to-noise ratio of 10. LOQ were below 100 fmol for all but NMN (1 pmol), ATP (1 pmol), NA (2.5 pmol), and uridine (3.1 pmol). Moreover, the LOQ using this method was at least 3-fold lower for seven metabolites than the previously used method. The previous method is 3-fold more sensitive for one metabolite (Table 3) [3].

**Metabolite Measurement Challenges**

In our hands, AMP and NADPH cannot be reliably quantified by these methods. ATP and ADP fragment on source to AMP, similar to NR fragmentation to Nam (Figure 2B Nam extracted ion current). Given poor resolution of AMP from both metabolites, detected AMP signal would represent biological AMP as well as that derived from ATP and ADP. Further, the NADP peak may represent the sum of cellular NADPH and a portion of cellular NADP⁺, which has become oxidized. Thus, care should be taken in interpreting the NADP peak.

Nam is strikingly membrane permeable. Nam in cells can be easily lost into post-cellular supernatants and we suspect that Nam in organelles can be easily lost into post-organelle supernatants.
LCMS-based Metabolomics

Table 3. LCMS/MS SRM parameters, sensitivity, and robustness for each metabolite.

| Metabolite | Transition (m/z) | CEa | Cone vol. | RT (min) | k' | LOQ this study (pmol)b | LOQ Evans (pmol)c | R² | RSD% Method | RSD% System |
|------------|-----------------|-----|-----------|----------|----|------------------------|------------------|----|-------------|-------------|
| Nam        | 123 > 96        | 16  | 32        | 9.82     | 6  | 0.6                    | 0.45             | 0.996 | 2           | 1           |
| NA         | 124 > 53        | 26  | 32        | 8.35     | 5  | 2.5                    | 1.2              | 0.999 | 2           | 1           |
| Cytidine   | 244 > 112       | 18  | 18        | 11.14    | 7  | 0.01                   | 0.1              | 0.995 | 22          | 16          |
| Uridine    | 245 > 113       | 16  | 18        | 11.5     | 7  | 3.1                    | 1.2              | 0.999 | 7           | 3           |
| NR         | 255 > 123       | 12  | 14        | 8.98     | 5.4| 0.01                   | 0.2              | 0.998 | 4           | 2           |
| NAR        | 256 > 124       | 13  | 14        | 10.33    | 6.4| 0.1                    | 0.06             | 0.948 | 11          | 12          |
| Inosine    | 269 > 137       | 12  | 12        | 12.88    | 8.2| 0.03                   | 0.07             | 0.974 | 10          | 5           |
| CMP        | 324 > 112       | 22  | 16        | 2.97     | 1.1| 0.09                   | 0.68             | 1     | 9           | 1           |
| UMP        | 325 > 97        | 12  | 20        | 4.11     | 1.9| 0.06                   | 0.21             | 0.99  | 6           | 4           |
| NMN        | 335 > 123       | 12  | 16        | 8.92     | 5.4| 1                      | 0.5              | 1     | 8           | 3           |
| NAMN       | 336 > 124       | 12  | 18        | 4.2      | 2  | 0.06                   | 0.18             | 0.999 | 10          | 2           |
| IMP        | 349 > 157       | 22  | 14        | 9.65     | 5.9| 0.1                    | 0.13             | 0.995 | 6           | 3           |
| ADP        | 428 > 136       | 26  | 30        | 10.43    | 6.5| 0.03                   | NIRf             | 0.999 | 8           | 3           |
| ATP        | 508 > 410       | 16  | 30        | 10.51    | 6.5| 1                      | NIRf             | 0.995 | 11          | 3           |
| ADP        | 560 > 348       | 16  | 26        | 11.08    | 6.9| 0.02                   | NIRf             | 0.991 | 3           | 4           |
| NAD'       | 664 > 428       | 26  | 26        | 13.64    | 8.7| 0.19                   | 0.17             | 0.999 | 8           | 2           |
| NAAD       | 665 > 428       | 24  | 24        | 11.89    | 7.5| 0.02                   | 0.26             | 0.998 | 12          | 2           |
| NADH       | 666 > 649       | 20  | 26        | 12.98    | 12 | 0.19                   | 0.06             | 0.988 | 10          | 3           |
| NADP       | 744 > 604       | 18  | 26        | 12.01    | 7.6| 0.06                   | 0.87             | 0.996 | 13          | 3           |
| NADPH      | 745 > 729       | 48  | 28        |          |    |                        |                  |       |             |             |

aCollision energy
bLOQ of method described in this paper
cLOQ of method in [3]
dRSD expressed as percentage of the mean

Results in mammalian cell line

To test our method on a real sample, we analyzed a glioma cell line, LN428/MPG (a gift of Dr. Robert Sobol, University of Pittsburgh), which had been grown in MEMalpha (10% FBS, HI, gentamycin, geneticin) media in triplicate 150 mm dishes (2 x 10⁶ cells per dish by CASY cell count). The results of the analysis are reported in Table 4. As expected, nucleotides, such as ATP, ADP, UMP, and NAD+, are high in abundance compared to NAD6 precursors and biosynthetic intermediates. The NAD6:NADH ratio is ~39 and the NAD6:NADP ratio is 4.6. As expected for cells grown in a type of Dulbecco’s modified Eagle’s media, Nam but not other vitamins is detectable. The concentration of NMN is low when compared with yeast, suggesting the NMN pool is converted rapidly to NAD6 [3].

Conclusions

Here, an improved LC-MS method has been developed to quantify the NAD6 metabolome. Its principle features are resolution and quantification of 16 metabolites in an alkaline separation, and resolution and separation of 3 metabolites in an acidic separation, both on a porous graphitic carbon stationary phase. The problem of ionization suppression that plagued earlier methods has been eliminated. Preservation and quantification of NADPH remains a challenge.

Table 4. NAD6 metabolism of LN428/MPG Cell Line.

| Metabolite | LN428/MPG Cells (µM) |
|------------|-----------------------|
| ATP        | 1010 ± 380            |
| ADP        | 890 ± 150             |
| UMP        | 370 ± 80              |
| NAD'       | 260 ± 40              |
| Inosine    | 250 ± 150             |
| Uridine    | 210 ± 80              |
| CMP        | 170 ± 70              |
| IMP        | 98 ± 26               |
| NADP       | 57 ± 10               |
| Nam        | 39 ± 2                |
| Cytidine   | 6.7 ± 4.4             |
| NADH       | 6.7 ± 2.3             |
| ADP        | 6.7 ± 2.2             |
| NMN        | 1.3 ± 0.3             |
| NA         | <4.0                  |
| NR         | <0.016                |
| NAMN       | <0.68                 |
| NAAD       | <0.24                 |
| NAR        | <1.1                  |
| NAD6/NADH  | 39                    |
Acknowledgements

Work was supported in part, by grant MCB-0822581 from the National Science Foundation and by NIH Pre-Doctoral Training Program in Genetics T32 grant GM008629.

Citation

Trammell SAJ, Brenner C (2013) Targeted, LCMS-based Metabolomics for Quantitative Measurement of NAD+ Metabolites Computational and Structural Biotechnology Journal. 4 (5): e201301012. doi: http://dx.doi.org/10.5936/csbj.201301012

References

1. Belenky P, Bogan KL, Brenner C (2007) NAD+ metabolism in health and disease. Trends Biochem Sci 32: 12-19.
2. Bogan KL, Brenner C (2008) Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr 28: 115-130.
3. Evans C, Bogan KL, Song P, Burant CF, Kennedy RT, et al. (2010) NAD+ metabolite levels as a function of vitamins and calorie restriction: evidence for different mechanisms of longevity. BMC Chem Biol 10: 2.
4. Panizzo C, Nawara M, Suski C, Kucharzycka R, Skoneczny M, et al. (2002) Aerobic and anaerobic NAD+ metabolism in Saccharomyces cerevisiae. FEBS Lett 517: 97-102.
5. Preis J, Handler P (1958) Biosynthesis of diphosphoryridine nucleotide. I. Identification of intermediates. J Biol Chem 233: 488-492.
6. Ghislain M, Talla E, Francois JM (2002) Identification and functional analysis of the Saccharomyces cerevisiae nicotinamide gene, PNC1. Yeast 19: 215-224.
7. Bieganowski P, Brenner C (2004) Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117: 495-502.
8. Domergue R, Castano I, De Las Penas A Zupancic M, Lockatell V, et al. (2005) Nicotinic acid limitation regulates silencing of Candida adsuris during UTL. Science 308: 866-870.
9. Houtkooper RH, Pirinen E, Auwerx J (2012) Sirtrins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13: 225-238.
10. Du J, Zhou Y, Su X, Yu JJ, Khan S, et al. (2011) Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334: 806-809.
11. Aarhus R, Graeff RM, Dickey DM, Walseth TF, Lee HC (1995) ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP+. J Biol Chem 270; 30327-30333.
12. Bieganowski P, Pace HC, Brenner C (2003) Eukaryotic NAD+ synthetase Qns1 contains an essential, obligate intramolecular thiol glutamine amidotransferase domain related to nitrilase. J Biol Chem 278: 33049-33055.
13. Belenky P, Christensen KC, Gazzaniga F, Pletnev AA, Brenner C (2009) Nicotinamide ribose and nicotinic acid ribose riboside in fungi and mammals. Quantitative basis for Urh1 and purine nucleoside phosphorylase function in NAD+ metabolism. J Biol Chem 284: 158-164.
14. Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14; 1431-1437.
15. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430.
16. Rongeaux A, Shea RJ, Mulks MH, Gidot D, Urbain J, et al. (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32: 3225-3234.
17. Revollo JR, Korner A, Mills KR, Satoh A, Wang T, et al. (2007) Namp/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363-375.
18. Hara N, Yamada K, Shibata T, Osago H, Tsuichya M (2011) Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS One 6: e22781.
19. Taguchi H, Sakaguchi M, Yamaki K, Shimabayashi Y (1987) Biosynthesis of trigonelline in the coffee plant. Nippon Nagelkagaku Kaishi-Journal of the Japan Society for Bioscience Biotechnology and Agrochemistry 61: 183-189.
20. Uptmeier B, Gross W, Koester S, Barz W (1988) Purification and properties of Sadenosyl-L-methionine:Nicotinic acid-N- methyltransferase from cell suspension cultures of Glycine max L. Archives of Biochemistry and Biophysics 262: 445-454.
21. Aksoy S, Brandriff BF, Ward A, Little PFR, Weinshilboum RM (1995) Human Nicotinamide-N-Methyltransferase Gene: Molecular Cloning, Structural Characterization and Chromosomal Localization. Genomics 29: 555-561.
22. Aoyama K, Matsubara K, Kondo M, Murakawa Y, Suno M, et al. (2001) Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson’s disease. Neurosci Lett 298: 78-80.
23. Fukushima T, Kaetsu A, Lim H, Moriyama M (2002) Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson’s disease. Exp Toxicol Pathol 53: 469-473.
24. Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB (2003) High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson’s disease. Neurosci Lett 342: 13-16.
25. Roessler M, Rollinger W, Palme S, Hagmann ML, Berndt P, et al. (2005) Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 11: 6550-6557.
26. Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D (2008) Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 27: 6679-6689.
27. Chlupicki S, Swies J, Mogielnicki A, Buczko W, Bartus M, et al. (2007) 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/protacycin pathway. Br J Pharmacol 152: 230-239.
28. Domagała TB, Szefler A, Dobrucki LW, Dropinski J, Polanski S, et al. (2012) Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels. Hypertension 59: 825-832.
29. Chlupicki S, Kurzdziel M, Sternak M, Szafraz M, Szymura-Oleskia J, et al. (2012) Single bout of endurance exercise increases NNM1 activity in the liver and RNA concentration in plasma: the role of IL-6. Pharmacol Rep 64: 369-376.
30. Bogan KL, Evans C, Belenky P, Song P, Burant CF, et al. (2009) Identification of Lsn1 and Sdr1 as glucose- and vitamin-regulated
nicotinamide mononucleotide and nicotinic acid mononucleotide [corrected] 5'-nucleotidases responsible for production of nicotinamide riboside and nicotinic acid riboside. J Biol Chem 284: 34861-34869.
31. Belenky P, Racette FG, Bogan KL, McClure JM, Smith JS, et al. (2007) Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Ubr1/Pup1/Meu1 pathways to NAD+. Cell 129: 473-484.
32. Tempel W, Rabeh WM, Bogan KL, Belenky P, Wojcik M, et al. (2007) Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol 5: e263.
33. Yoshino J, Mills KF, Yoon MJ, Imai S (2011) Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 14: 528-536.
34. Nikiforov A, Dolle C, Niere M, Ziegler M (2011) Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem 286: 21767-21778.
35. Garavaglia S, Bruzzone S, Cassani G, Canella L, Allegrone G, et al. (2012) The high-resolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism. Biochim J 441: 131-141.
36. Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, et al. (2012) The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 15: 838-847.
37. Todisco S, Agrimi G, Castegna A, Palmieri F (2006) Identification of the mitochondrial NAD+ transporter in Saccharomyces cerevisiae. J Biol Chem 281: 1524-1531.
38. Bieganski P, Seillé HF, Wojcik M, Brenner C (2006) Synthetic lethal and biochemical analyses of NAD and NADH kinases in Saccharomyces cerevisiae establish separate functions of cellular functions. J Biol Chem 281: 22439-22445.
39. Kornberg A (1948) The participation of inorganic pyrophosphate in the reversible enzymatic synthesis of diphosphopyridine nucleotide. J Biol Chem 176: 1475.
40. Newman JC, He W, Verdin E (2012) Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. J Biol Chem 287: 42436-42443.
41. Lerner F, Niere M, Ludwig A, Ziegler M (2001) Structural and functional characterization of human NAD kinase. Biochem Biophys Res Commun 288: 69-74.
42. Ohashi K, Kawai S, Murata K (2012) Identification and characterization of a human mitochondrial NAD kinase. Nat Commun 3: 1248.
43. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P (2009) Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 324: 654-657.
44. Lu SP, Lin SJ (2011) Phosphate-responsive signaling pathway is a novel component of NAD+ metabolism in Saccharomyces cerevisiae. J Biol Chem 286: 14271-14281.
45. Brenner C (2011) On the nonspecific degradation of NAD+ to nicotinamide riboside. J Biol Chem 286: le5; author reply le6.
46. Lorent MO, Pedersen L, Francois J (2007) Revised procedures for yeast metabolites extraction: application to a glucose pulse to carbon-limited yeast cultures, which reveals a transient activation of the purine salvage pathway. Yeast 24: 47-60.
47. Wu JT, Wu LH, Knight JA (1986) Stability of NADPH: effect of various factors on the kinetics of degradation. Clin Chim Acta 32: 314-319.
48. Sherman F (1991) Getting started with yeast. Methods Enzymol 194: 3-21.
49. Zhao L, Kroenke C, Song J, Piwnica-Worms D, Ackerman J, et al. (2008) Intracellular water-specific MR of microbead-adherent cells: the HeLa cell intracellular water exchange lifetime. NMR in biomedicine 21: 159-164.
50. Kołodziejka-Huben M, Kamińska Z, Paneth P (2002) Preparation of 18O-labelled nicotinamide. Journal of Labelled Compounds and Radiopharmaceuticals 45: 1005-1010.
51. Yang T, Chan NY, Sauve AA (2007) Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. J Med Chem 50: 6458-6461.
52. Xing J, Apedo A, Tymiaik A, Zhao N (2004) Liquid chromatographic analysis of nucleosides and their mono-, di- and triphosphates using porous graphitic carbon stationary phase coupled with electrospray mass spectrometry. Rapid Commun Mass Spectrom 18: 1599-1606.
53. Jansen RS, Rosing H, Schellens JH, Beijnen JH (2009) Retention studies of 2′-2′-difluorodeoxyuridine and 2′-2′-difluorodeoxy uridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method. J Chromatogr A 1216: 3168-3174.
54. Pabst M, Grass J, Fisched R, Leonard R, Jin C, et al. (2010) Nucleotide and nucleotide sugar analysis by liquid chromatography-electrospray ionization-mass spectrometry on surface-conditioned porous graphitic carbon. Anal Chem 82: 9782-9788.
55. Smith CA, O’Maille G, Want EJ, Qin C, Trauger SA, et al. (2005) METLIN: a metabolite mass spectral database. Ther Drug Monit 27: 747-751.
56. Horai H, Arita M, Kanaya S, Nihei Y, Ikeda T, et al. (2010) MassBank: a public repository for sharing mass spectral data for life sciences. J Mass Spectrom 45: 703-714.